相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Close Association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or*60 Haplotype and Its Apparent Influence on 7-Ethyl-10-hydroxycamptothecin (SN-38) Glucuronidation in Japanese
Yoshiro Saito et al.
DRUG METABOLISM AND DISPOSITION (2009)
Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
Erika Cecchin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Federico Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
B. Glimelius et al.
ANNALS OF ONCOLOGY (2008)
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
D. M. Kweekel et al.
BRITISH JOURNAL OF CANCER (2008)
UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma
Chun-Yu Liu et al.
CANCER (2008)
Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics - To test or not to test, that is the question
John F. Deeken et al.
CANCER (2008)
Clinical and pharmacogenetic factors associated with irinotecan toxicity
Dinemarie Kweekel et al.
CANCER TREATMENT REVIEWS (2008)
Pharmacogenetics in colorectal cancer: a systematic review
Silvia Funke et al.
PHARMACOGENOMICS (2008)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
A. Ruzzo et al.
PHARMACOGENOMICS JOURNAL (2008)
Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer:: A proposal for standardization of patient characteristic reporting and stratification
H. Sorbye et al.
ANNALS OF ONCOLOGY (2007)
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer
Ji-Youn Han et al.
CANCER (2007)
Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities
Marwan G. Fakih et al.
CLINICAL COLORECTAL CANCER (2007)
Insights, challenges, and future directions in irinogenetics
Tae Won Kim et al.
THERAPEUTIC DRUG MONITORING (2007)
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan
Jean-Francois Cote et al.
CLINICAL CANCER RESEARCH (2007)
UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females
J. Mercke Odeberg et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin
Ji-Youn Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy
C Massacesi et al.
CANCER (2006)
Pharmacogenetics of irinotecan:: A promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan
M Ando et al.
INVESTIGATIONAL NEW DRUGS (2005)
Pharmacogenetics of folate-related drug targets in cancer treatment
K Robien et al.
PHARMACOGENOMICS (2005)
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study
E Van Cutsem et al.
BRITISH JOURNAL OF CANCER (2005)
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity
A Jakobsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Benefit-risk assessment of irinotecan in advanced colorectal cancer
B Glimelius
DRUG SAFETY (2005)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity:: A molecular and clinical study of 75 patients
E Rouits et al.
CLINICAL CANCER RESEARCH (2004)
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38
L Paoluzzi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia
K Robien et al.
CLINICAL CANCER RESEARCH (2004)
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer
K Sai et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Detection of the four sequence variations of MDR1 gene using TaqMan® MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects
K Saito et al.
CLINICAL BIOCHEMISTRY (2003)
A comparison of Bayesian methods for haplotype reconstruction from population genotype data
M Stephens et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Comparison of methods for DNA extraction from paraffin-embedded tissues and buccal cells
W Cao et al.
CANCER DETECTION AND PREVENTION (2003)
Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan
K Sai et al.
PHARMACOGENETICS (2003)
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer
B Glimelius et al.
ANNALS OF ONCOLOGY (2002)
Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy
M Holthe et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
